X0306 4 2020-12-03 0000882796 BIOCRYST PHARMACEUTICALS INC BCRX 0001385496 Stonehouse Jon P 4505 EMPEROR BLVD. SUITE 200 DURHAM NC 27703 1 1 President & CEO Emp. Stock Option (Right to Buy) 5.45 2020-12-03 4 A 0 25000 0 A 2020-12-03 2023-08-08 Common Stock 25000 25000 D Emp. Stock Option (Right to Buy) 3.23 2020-12-03 4 A 0 157250 0 A 2020-12-18 2029-12-17 Common Stock 157250 157250 D On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based stock options awarded to the reporting person on August 8, 2013 has been met. Therefore, 25% of such performance-based stock options vested on December 3, 2020. On December 3, 2020, the U.S. Food and Drug Administration approved oral, once-daily ORLADEYO? (berotralstat) for prophylaxis to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years and older. As a result, one of the vesting criteria associated with the performance-based options awarded to the reporting person on December 17, 2019 has been met. Therefore, 50% of such performance based stock options will vest upon satisfaction of the minimum vesting period of twelve months and one day from the date of grant, which period ends on December 18, 2020. /s/ Alane P. Barnes, by power of attorney 2020-12-07